Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials.
about
Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomyIntravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema.The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema.Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant.Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting.
P2860
Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Baseline visual acuity strongl ...... actor treatment across trials.
@en
Baseline visual acuity strongl ...... actor treatment across trials.
@nl
type
label
Baseline visual acuity strongl ...... actor treatment across trials.
@en
Baseline visual acuity strongl ...... actor treatment across trials.
@nl
prefLabel
Baseline visual acuity strongl ...... actor treatment across trials.
@en
Baseline visual acuity strongl ...... actor treatment across trials.
@nl
P2093
P2860
P356
P1476
Baseline visual acuity strongl ...... actor treatment across trials.
@en
P2093
Andreas Wenzel
Jessica Vögeler
Jost Hillenkamp
Marie-Catherine Mousseau
Pascale Massin
Philippe Margaron
Pravin U Dugel
Ron Hashmonay
Sobha Sivaprasad
P2860
P304
P356
10.2147/OPTH.S100764
P407
P577
2016-06-14T00:00:00Z